Dyne Therapeutics expects Q1 registrational data from a 71-patient DM1 expansion cohort and plans a Q1 U.S. launch for DMD. Its Phase III confirmatory trial will enroll 150 patients randomized one-to-one.
DYN · Dyne Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 33%
- Last earnings
- Sep 3, 2024
- Latest filing
- 10-Q · Nov 5
- Price history
- Sep 2020 to Nov 2026
Latest documents
Dyne Therapeutics, Inc. reported a $193.6 million quarterly net loss and $1.134 billion in cash, cash equivalents and marketable securities, with funding expected into the second quarter of 2028; z-rostudirsen’s FDA PDUFA target action date is January 21, 2027.
Dyne Therapeutics’ FDA accepted the BLA for z-rostudirsen in DMD, with priority review and a PDUFA target date of January 21, 2027; potential U.S. launch is expected in the first quarter of 2027.
Dyne Therapeutics announced additional ACHIEVE trial data showing z-basivarsen improved myotonia, function, strength and patient-reported outcomes in a pooled dose group, with no related serious adverse events reported; ACHIEVE registrational expansion cohort topline data are planned for Q1 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| general and administrative headcount | 44 | the three months ended June 30, 2026 filing | — |
| Participants enrolled in registrational expansion cohort (ACHIEVE) | 71 | June 2026 | — |
| research and development headcount | 39 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DYN
this stock
Dyne Therapeutics, Inc.
|
$2.90B | -20.8% | — | — | 13.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 25
Dyne Therapeutics expects Q1 registrational data from a 71-patient DM1 expansion cohort and plans a Q1 U.S. launch for DMD. Its Phase III confirmatory trial will enroll 150 patients randomized one-to-one.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DYN | -9.7% | -0.8% | -10.1% | -7.1% | -20.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -1.1% | +8.5% | -0.9% | +1.6% | -21.9% |